中性粒细胞CD64在血液肿瘤患者病原微生物感染诊断中的应用现状

Current application status of neutrophil CD64 in diagnosis of pathogenic microbial infection in patients with hematological neoplasms

对血液肿瘤患者病原微生物感染的诊断,仍然是临床工作的挑战,患者发生感染后临床表现不典型,且死亡风险极高,因此需要兼具敏感度及特异度的生物标志物早期识别感染的发生。目前研究已证实,中性粒细胞CD64(nCD64)在血液肿瘤患者感染中的诊断价值,联合nCD64和其他具有潜力的生物标志物,如细胞因子等,可能进一步提高感染诊断的准确性,帮助临床早期诊断血液肿瘤患者的感染,并指导治疗,降低患者病死率。为了进一步了解血液肿瘤患者感染诊断中的生物标志物,笔者拟就nCD64单一生物标志物和联合其他生物标志物检测在血液肿瘤患者病原微生物感染诊断中的应用现状进行阐述。

Diagnosis of pathogenic microbial infection in patients with hematological neoplasms is still a challenge in clinical work.Pathogenic microbial infection in patients with hematological neoplasms has atypical clinical manifestations and a high risk of death.Therefore,biomarkers with both sensitivity and specificity are needed to identify occurrence of infection in the early stage.Current studies have confirmed diagnostic value of neutrophil CD64(nCD64)for infection in patients with hematological neoplasms.nCD64 combined with other potential biomarkers,such as cytokines,may further improve current accuracy of diagnosis,help clinical early diagnosis of infection and guide treatment,and reduce fatality of patients with hematological neoplasms.In order to learn more about biomarkers in diagnosis of infection in patients with hematological neoplasms,this article intends to summarize current application status of nCD64 single biomarker and combined with other biomarkers detection in diagnosis of pathogenic microbial infection in patients with hematological neoplasms.